<DOC>
	<DOCNO>NCT01798849</DOCNO>
	<brief_summary>This study evaluate safety , tolerability effect central diastolic blood pressure ( cDBP ) MK-8892 give single oral dos healthy male participant ( Panel A B ) male participant mild-to-moderate hypertension ( Panel C ) .</brief_summary>
	<brief_title>A Rising Single Dose Study Safety , Tolerability , Pharmacokinetics ( PK ) Pharmacodynamics MK-8892 ( MK-8892-001 )</brief_title>
	<detailed_description>Up three plan panel either 8 healthy participant ( Panels A B ) 8 participant mild moderate hypertension ( Panel C ) enrol . In Panels A B , 8 participant alternately receive single rise dos MK-8892 placebo . All dos administer fasted state , except Panel A , Period 5 standard high-fat breakfast provide approximately 30 minute prior dose . Panel A begin first . At least 3 day elapse participant alternate panel ( Panel B ) receive next high dose . In Panel C , 8 mild moderate hypertensive male participant receive single rise dos MK-8892 placebo . Panel C may begin first 4 period Panels A B complete dosing . For panel , least 7 day washout treatment period give participant . Participants may enrol one panel study . Subsequent dos panel administer careful evaluation safety , tolerability , pharmacodynamic effect give dose .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<criteria>Systolic blood pressure ( SBP ) &gt; 110 ≤ 140 mmHg Panels A B , SBP value 140175 mmHg diastolic blood pressure ( DBP ) 90105 mmHg least three different occasion prestudy ( screen ) visit Panel C. Participants treat medication hypertension may include long titrated medication Body Mass Index ( BMI ) ≥ 18 kg/m^2 ≤ 32 kg/m^2 Healthy ( exception hypertensive subject Panel C ) No clinically significant abnormality electrocardiogram ( ECG ) No history clinically significant cardiac disease No history heart failure Nonsmoker and/or use nicotine nicotinecontaining product least 6 month Mentally legally incapacitate History stroke , chronic seizure , major neurological disorder History clinically significant endocrine , gastrointestinal , cardiovascular ( except mild moderate hypertension ) , hematological , hepatic , immunological , renal , respiratory , genitourinary abnormality diseases Functional disability interfere rise sit position stand position History cancer ( malignancy ) History significant multiple and/or severe allergy ( e.g . food , drug , latex allergy ) , anaphylactic reaction significant intolerability prescription nonprescription drug food Positive hepatitis B , hepatitis C , Human Immunodeficiency Virus ( HIV ) Has major surgery , donate lose 1 unit blood participate another investigational study within 4 week Has participate another investigational trial within 4 week Unable refrain anticipates use medication study Anticipates use medication erectile dysfunction study Uses anticipate use organic nitrate study ( e.g . nitroglycerin , isosorbide mononitrate , isosorbide dinitrate , pentaerythritol ) Anticipates use cytochrome P450 inhibitor ( e.g . ketoconazole ) inducer ( e.g . rifampin ) study Consumes excessive amount alcohol , define great 3 glass alcoholic beverage per day Consumes excessive amount , define great 6 serving coffee , tea , cola , caffeinated beverage per day Regular user ( include recreational user ) illicit drug history drug ( include alcohol ) abuse within approximately 1 year</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>